Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029536 · ClinicalTrials.gov registry record · Phase 3
Progesterone vs Placebo Therapy for Women With Epilepsy
A Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 294
- Enrollment target
NCT00029536 is a Phase 3 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 294 participants.
The verdict
NCT00029536, a Phase 3 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 294 participants
- Enrollment target
Study Summary
The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.
Interventions
- BIOLOGICAL Progesterone Lozenges
- OTHER Matched Placebo Lozenges
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2000-10 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029536
The ClinicalTrials.gov registry entry for NCT00029536 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Progesterone Lozenges is the first listed.
NCT00029536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029536 about?
NCT00029536 is a clinical study titled "Progesterone vs Placebo Therapy for Women With Epilepsy". The purpose of this investigation was to determine if cyclic adjunctive progesterone supplement is superior to placebo in the treatment of intractable seizures in women with and without catamenial epilepsy.
What is the current status of trial NCT00029536?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 2000-10. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00029536?
The interventions under investigation include: Progesterone Lozenges (BIOLOGICAL), Matched Placebo Lozenges (OTHER).
Who is sponsoring clinical trial NCT00029536?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.